1)Bakaki PM, et al:Defining pediatric polypharmacy:A scoping review. PLoS One 13:e0208047, 2018
2)薬剤耐性ワンヘルス動向調査検討会:薬剤耐性ワンヘルス動向調査2018. https://www.mhlw.go.jp/content/10900000/000415561.pdf(2019年8月閲覧)
3)奥村泰之,他:日本における子どもへの向精神薬処方の経年変化:2002年から2010年の社会医療診療行為別調査の活用.精神神経学雑誌116:921-935, 2014
4)Dai D, et al:Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in ICUs of U. S. children's hospitals. Pediatr Crit Care Med 17:e218-228, 2016
5)Feinstein J, et al:Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals. Pediatrics 135:e99-108, 2015
6)Rashed AN, et al:Risk factors associated with adverse drug reactions in hospitalised children:International multicentre study. Eur J Clin Pharmacol 68:801-810, 2012
7)Knopf H, Du Y:Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany. Br J Clin Pharmacol 70:409-417, 2010